CLYM

Climb Bio, Inc.'s stock price has increased by over 521% in the past six months. Key events impacting the stock price include the FDA Fast Track Designation for Budoprutug, positive topline Phase 1 subcutaneous data for Budoprutug, Q1 2026 results beating EPS estimates, a $110 million private placement, and bullish analyst coverage.